AFT Pharmaceuticals - A Bumpy Road
While it stated this was due to weaker-than-expected Australasian sales, relative to our expectations it was gross margins remaining soft.
257 Views
AFT Pharmaceuticals - 1H24 Result — Not Without Some Pain
The key positive was underlying non-ANZ sales growth of +95% versus 1H23, which, coupled with ongoing solid ANZ performance, more than offset gross...
460 Views
AFT Pharmaceuticals - FDA Pain Is Over
AFT Pharmaceuticals (AFT) has finally received the long awaited US FDA approval for its Maxigesic IV product (hospital-based product)
442 Views
AFT Pharmaceuticals: FY23 Result — On Script
We liked what we saw in AFT Pharmaceuticals' (AFT) FY23 result: (1) ANZ revenue (AFT's core defensive growth driver) grew +24% versus FY22, (2)...
502 Views
AFT Pharmaceuticals (AFT): FY23 Result – First Impressions
AFT Pharmaceuticals (AFT) reported an operating FY23 result in-line with guidance and slightly ahead of our expectations with EBIT ex licensing...
455 Views